Log in

Synlogic Stock Price, News & Analysis (NASDAQ:SYBX)

$2.19
+0.02 (+0.92 %)
(As of 10/23/2019 08:54 AM ET)
Today's Range
$2.12
Now: $2.19
$2.22
50-Day Range
$2.02
MA: $2.32
$2.79
52-Week Range
$1.96
Now: $2.19
$11.43
Volume64,982 shs
Average Volume158,420 shs
Market Capitalization$69.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.57
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.52 million
Book Value$4.88 per share

Profitability

Net Income$-48,440,000.00
Net Margins-1,844.96%

Miscellaneous

Employees74
Market Cap$69.47 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.


Synlogic (NASDAQ:SYBX) Frequently Asked Questions

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

When did Synlogic's stock split? How did Synlogic's stock split work?

Synlogic's stock reverse split before market open on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

How were Synlogic's earnings last quarter?

Synlogic Inc (NASDAQ:SYBX) posted its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The biotechnology company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.96 million. Synlogic had a negative net margin of 1,844.96% and a negative return on equity of 34.75%. View Synlogic's Earnings History.

When is Synlogic's next earnings date?

Synlogic is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Synlogic.

What price target have analysts set for SYBX?

8 analysts have issued 12-month target prices for Synlogic's shares. Their forecasts range from $2.00 to $25.00. On average, they expect Synlogic's stock price to reach $16.00 in the next year. This suggests a possible upside of 630.6% from the stock's current price. View Analyst Price Targets for Synlogic.

What is the consensus analysts' recommendation for Synlogic?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synlogic.

What are Wall Street analysts saying about Synlogic stock?

Here are some recent quotes from research analysts about Synlogic stock:
  • 1. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (10/19/2019)
  • 2. HC Wainwright analysts commented, "We calculate an enterprise value of $480M, comprised of $280M for I/O portfolio. This yields a price objective of $13.00 per share, with approximately 37M fully-diluted shares outstanding as of mid-2020 (including exercise of approximately 2.5M outstanding options and all of the roughly 2.5M pre-funded warrants previously issued in the last private placement transaction)." (9/9/2019)

Has Synlogic been receiving favorable news coverage?

News coverage about SYBX stock has been trending negative on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Synlogic earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Synlogic.

Who are some of Synlogic's key competitors?

What other stocks do shareholders of Synlogic own?

Who are Synlogic's key executives?

Synlogic's management team includes the folowing people:
  • Dr. Peter Barrett, Exec. Chairman (Age 66)
  • Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)
  • Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Pres, CEO, Chief Medical Officer & Director (Age 43)
  • Prof. Timothy K. Lu, Co-Founder
  • Dr. James J. Collins, Co-Founder

Who are Synlogic's major shareholders?

Synlogic's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Flagship Harbor Advisors LLC (0.05%). View Institutional Ownership Trends for Synlogic.

Which institutional investors are buying Synlogic stock?

SYBX stock was purchased by a variety of institutional investors in the last quarter, including Flagship Harbor Advisors LLC. View Insider Buying and Selling for Synlogic.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $2.19.

How big of a company is Synlogic?

Synlogic has a market capitalization of $69.47 million and generates $2.52 million in revenue each year. The biotechnology company earns $-48,440,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. Synlogic employs 74 workers across the globe.View Additional Information About Synlogic.

What is Synlogic's official website?

The official website for Synlogic is http://www.synlogictx.com/.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]


MarketBeat Community Rating for Synlogic (NASDAQ SYBX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  461
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel